#BCRX

2 weeks ago

BioCryst Reports Full Year 2025 Financial Results and Provides Business Update BioCryst (Nasdaq: BCRX) reported full year 2025 results and a business update on Feb 26, 2026. ORLADEYO net revenue was $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO). The company achieved record GAAP and non-GAAP operating profit, completed the Astria acquisition, and received FDA approval for ORLADEYO pellets for ages 2 to <12.BioCryst maintained 2026 ORLADEYO revenue guidance of $625–$645 million and full year total revenue guidance of $635–$660 million.

#BCRX BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/BCRX/bio-cryst-repo...

0 0 0 0

StockTitan

@stocktitan.net

1 month ago

BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema BioCryst (Nasdaq: BCRX) completed its acquisition of Astria Therapeutics on Jan 23, 2026 for an implied value of approximately $700 million (net of Astria cash). The deal adds navenibart, a Phase 3 long‑acting plasma kallikrein inhibitor with potential every‑three and every‑six month dosing, to BioCryst’s hereditary angioedema (HAE) franchise alongside the oral therapy ORLADEYO. BioCryst financed the cash portion using on‑hand cash and approximately $396.6 million drawn from a Blackstone‑managed financing facility, and issued about 37.3 million shares to Astria equity holders. Leadership additions from Astria join BioCryst’s board and technical ranks to support development and commercialization.

#BCRX BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema

www.stocktitan.net/news/BCRX/bio-cryst-comp...

1 0 0 0

InsiderFinance

@insiderfinance.com

3 months ago

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#RH, #TGB, #BCRX, #LFST, #CLS

#OptionFlow #OptionsTrading #Trading

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years – ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older – -Oral pellet formulation provides child-friendly method of administration- –Showed early and sustained reductions in monthly attack rates in APeX-P– RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2025

#BCRX BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years

www.stocktitan.net/news/BCRX/bio-cryst-anno...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

#BCRX BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/BCRX/bio-cryst-repo...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

5 months ago

Trade Alerts, Tuesday October 14, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Tue Oct 14th - #PFAI #OP #NEXM #HVII #SEED #QH #BYND #BCRX #BCAB #ALBT #SOJD #OEC #NMG - More: crystalequityresearch.com/trade-alerts... - #smallcap

1 0 0 0

StockTitan

@stocktitan.net

5 months ago

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile –Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst’ s HAE portfolio–. –Implied aggregate equity-value of approximately $920 million and implied enterprise value of approximately $700 million–. RESEARCH TRIANGLE PARK, N.C.,& BOSTON---- BioCryst Pharmaceuticals, Inc. and Astria...

#ATXS #BCRX BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

www.stocktitan.net/news/ATXS/bio-cryst-to-a...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update BioCryst Pharmaceuticals (Nasdaq:BCRX) reported outstanding Q2 2025 financial results, marking the company's best quarter historically. ORLADEYO net revenue reached $156.8 million, up 45% year-over-year, with total revenues of $163.4 million. The company achieved an operating profit of $29.8 million (+239% y-o-y) and non-GAAP operating profit of $57.0 million.Key highlights include record-breaking new patient prescriptions, increased prescriber base, and lower discontinuation rates. BioCryst made a $50 million debt paydown in July and plans to retire all remaining term debt using proceeds from the sale of its European ORLADEYO business. The company maintains its 2025 ORLADEYO revenue guidance of $580-600 million and expects positive cash flows for the full year.The rare disease pipeline continues advancing with ORLADEYO granules for children (PDUFA date: December 12, 2025) and expected initial data from BCX17725 and avoralstat programs by year-end.

#BCRX BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/BCRX/bio-cryst-repo...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

BioCryst Unveils Groundbreaking Research on HAE Treatment Burden in Young Patients Under 12 Latest findings reveal treatment challenges for young HAE patients and caregivers. New data from pediatric studies and patient perspectives to be presented. Learn more.

#BCRX BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

www.stocktitan.net/news/BCRX/bio-cryst-to-h...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

BioCryst Secures $264M Deal: European ORLADEYO Sale to Slash Debt and Boost Cash Position by $400M Strategic sale includes $250M upfront payment, eliminates $70M in interest costs. BioCryst projects $700M cash position by 2027. Get full transaction details.

#BCRX BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

www.stocktitan.net/news/BCRX/bio-cryst-anno...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI BioCryst Pharmaceuticals presented new data demonstrating the long-term efficacy and safety of ORLADEYO (berotralstat) for hereditary angioedema (HAE) treatment across all age groups at EAACI 2025. Key findings from four studies showed: (1) In pediatric patients, an 86% reduction in attacks requiring professional care was observed after 12 weeks of treatment. (2) The Berolife study showed sustained attack reduction in patients aged >12 years, with median monthly attacks decreasing from 1.0 to 0.44 after six months. (3) Quality of life studies revealed significant improvements in patient outcomes, with 60% achieving Minimal Clinically Important Difference at week 24. (4) Focus group results indicated positive patient experiences, including better disease control and easier treatment management compared to previous therapies. The drug demonstrated consistent safety across all studies, with common side effects including nasopharyngitis and headache.

#BCRX BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

www.stocktitan.net/news/BCRX/bio-cryst-pres...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

ORLADEYO® (berotralstat) Approved in Colombia BioCryst Pharmaceuticals (BCRX) has received approval from Colombia's National Institute of Drug and Food Surveillance (INVIMA) for ORLADEYO (berotralstat), an oral, once-daily treatment for hereditary angioedema (HAE) attack prevention in patients aged 12 and older. This approval expands ORLADEYO's presence in the pan-Latin America region, where it's already approved in Chile, Argentina, Brazil, Mexico, and Peru. BioCryst's partnership with Pint Pharma GmbH involves exclusive collaboration for registration and promotion in the region, with Pint handling marketing authorizations and commercialization responsibilities.

#BCRX ORLADEYO® (berotralstat) Approved in Colombia

www.stocktitan.net/news/BCRX/orladeyo-berot...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

ORLADEYO Makes History: First Oral HAE Drug Now Reimbursed Across All Major European Markets First oral HAE prevention treatment achieves complete major European market access. Breakthrough therapy now available in 30+ countries. See market impact.

#BCRX BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

www.stocktitan.net/news/BCRX/bio-cryst-achi...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

New Clinical Data: ORLADEYO Slashes HAE Attacks by 64% in Groundbreaking Multi-Age Study Latest real-world studies reveal ORLADEYO's impact on HAE attack prevention from children to adults. See breakthrough efficacy data and patient outcomes. Get details.

#BCRX BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

www.stocktitan.net/news/BCRX/bio-cryst-high...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

FDA Fast-Tracks First-Ever Oral HAE Treatment for Children Under 12: September Decision Expected BioCryst's ORLADEYO aims to be first oral preventive therapy for hereditary angioedema in young children. PDUFA date set for September. See trial results.

#BCRX BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

www.stocktitan.net/news/BCRX/bio-cryst-anno...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

10 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Mon May 5th - #HL #RIG #RGTI #RXRX #FUBO #IBRX #AIFF #WULF #BCRX #OGN #PTON #WOLF #VLRS #QBTS #PTEN #NIXX #GPUS #CERS #CDE #ABR - More: crystalequityresearch.com/SmCpStr/ - #smallcap

1 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

10 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Mon May 5th - #ZCAR #UCAR #KWE #KDLY #IVF #FMST #STEC #SBET #QNCX #NCNA #MRIN #IMMP #FNGR #CTRM #BCRX #AIFF #VCSA - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

BioCryst Crushes Earnings: ORLADEYO Drug Sales Jump 51%, Company Fast-Tracks Path to Profits BioCryst raises ORLADEYO 2025 revenue guidance to $600M as paid patients surge to 84%. See how accelerated profitability timeline impacts growth strategy.

#BCRX BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/BCRX/bio-cryst-repo...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones BioCryst Pharmaceuticals (BCRX) reported strong Q4 and full year 2024 results, with ORLADEYO net revenue reaching $124.2M in Q4 (+36.6% y-o-y) and $437.7M for FY 2024 (+34.3% y-o-y). The company increased its FY 2025 ORLADEYO revenue guidance to $535-550M.The company achieved a non-GAAP operating profit of $62.9M in 2024 (excluding stock-based compensation) and expects to approach positive EPS and cash flow in 2H 2025. GAAP operating loss for 2024 was $2.5M, with Q4 net loss at $26.8M ($0.13 per share).Key pipeline developments include plans to expand ORLADEYO label to children aged 2-11, with NDA submission planned this year. Initial clinical data from BCX17725 for Netherton syndrome and avoralstat for diabetic macular edema are expected by year-end. Cash position stood at $342.8M as of December 31, 2024.

#BCRX BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

www.stocktitan.net/news/BCRX/bio-cryst-repo...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Can This Rare Disease Drug Eliminate HAE Attacks in Children? Clinical Trial Says Yes Groundbreaking pediatric trial shows ORLADEYO reduced HAE attacks from 1.5 to 0.3 monthly, with exceptional safety profile. FDA submission planned for 2024.

#BCRX BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years

www.stocktitan.net/news/BCRX/bio-cryst-anno...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Breakthrough: Portugal Gets First-Ever Daily Oral HAE Treatment as ORLADEYO Expands Global Reach BioCryst's ORLADEYO receives Portuguese approval as first oral, once-daily hereditary angioedema prevention therapy, expanding to 44 countries worldwide.

#BCRX BioCryst Launches ORLADEYO® (berotralstat) in Portugal

www.stocktitan.net/news/BCRX/bio-cryst-laun...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

BioCryst's ORLADEYO Hits $437M Revenue, Projects 20% Growth as Profitability Nears BioCryst reports 34% YoY growth for ORLADEYO, forecasts $535M revenue in 2025. Company achieves operating profit milestone and expects full profitability by 2026.

#BCRX BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

www.stocktitan.net/news/BCRX/bio-cryst-anno...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

#BCRX BioCryst Launches ORLADEYO® (berotralstat) in Ireland

www.stocktitan.net/news/BCRX/bio-cryst-laun...

0 0 0 0